The 15 most recent market catalysts affecting $MDGL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 5, 2026
Corporate Catalyst
Bearish
Impact 85
Law Firms Investigate Potential Securities Violations Following Whistleblower Complaint
Madrigal Pharmaceuticals is facing significant scrutiny due to investigations by several law firms. These probes stem from a whistleblower complaint by a former Senior VP, alleging…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 65
Madrigal Pharmaceuticals Announces New Real-World Data for Rezdiffra at AASLD 2026
Madrigal Pharmaceuticals released new real-world data for its MASH drug, Rezdiffra, at a major liver disease conference. The data indicated that a significant number of patients ex…
Nov 4, 2026
Corporate Catalyst
Bearish
Impact 65
Madrigal Pharmaceuticals Faces Whistleblower Retaliation Complaint
Madrigal Pharmaceuticals disclosed in its 10-Q that a former employee filed a lawsuit alleging retaliation under Sarbanes-Oxley, claiming they raised concerns about company data an…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Raises Price Target on Madrigal Pharmaceuticals to $743
Truist, a prominent financial institution, has raised its price target for Madrigal Pharmaceuticals (MDGL) to $743, up from $709, and maintained its 'Buy' rating. This positive rev…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 95
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results
Madrigal Pharmaceuticals announced a pivotal Q3 2026, achieving its first quarter of profitability with a net income of $55.4 million, a significant turnaround from a substantial l…
Oct 27, 2026
Corporate Catalyst
Neutral
Impact 55
Madrigal Pharmaceuticals to Present New Rezdiffra Data at AASLD The Liver Meeting 2026
Madrigal Pharmaceuticals is announcing its plan to present multiple abstracts on Rezdiffra at the AASLD Liver Meeting in November 2026. This filing is a forward-looking statement a…
Oct 6, 2026
Corporate Catalyst
Neutral
Impact 55
Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra
Madrigal Pharmaceuticals has published pre-specified secondary analysis data from its Phase 3 MAESTRO-NASH trial in a peer-reviewed journal. This publication specifically addresses…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target
Goldman Sachs, a prominent investment bank, has reinstated its 'Buy' rating on Madrigal Pharmaceuticals (MDGL) and set a substantial price target of $704. This action signals stron…
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725
Citigroup's initiation of coverage on Madrigal Pharmaceuticals with a 'Buy' rating and a $725 price target is a significant event for the company. Analyst initiations, especially w…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
Madrigal Pharmaceuticals shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a $605 price target.
This headline represents a strong corporate catalyst for Madrigal Pharmaceuticals. Analyst upgrades, especially with a significant price target increase like $605, often signal a r…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target
Wolfe Research's upgrade of Madrigal Pharmaceuticals (MDGL) to Outperform, coupled with a substantial $605 price target, indicates a strong positive sentiment from a reputable rese…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Madrigal Pharmaceuticals shares are trading lower. The company reported Q2 financial results.
The headline directly points to a corporate catalyst: Madrigal Pharmaceuticals' Q2 financial results. The 'trading lower' aspect indicates a negative market reaction, likely due to…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 85
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate
Madrigal Pharmaceuticals (MDGL) announced Q2 results that significantly exceeded analyst expectations on both the top and bottom lines. The company reported a loss of $(1.99) per s…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 65
Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685
Wells Fargo analyst Sadia Rahman initiated coverage on Madrigal Pharmaceuticals (MDGL) with an 'Overweight' rating and a substantial price target of $685. This is a significant eve…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 75
Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark Office
Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for Resmetirom (Rezdiffra), its recently approved drug for MASH. These patents extend protection for speci…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.